oxazoles has been researched along with Acute Confusional Senile Dementia in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Apuzzo, CF; Bothwell, PJ; Ferrence, GM; Hamaker, CG; Huffman, SE; Jones, MA; Oliver, EB; Platt, DC; Strandquist, ET; Webb, MI; Weitzel, CS; Will, MF; Yawson, GK | 1 |
| Beohar, M; Ganeshpurkar, A; Gutti, G; Kakarla, R; Krishnamurthy, S; Kumar, A; Kumar, D; Singh, SK | 1 |
| Dong, F; Jia, L; Li, W; Liu, W; Miao, C; Wang, M; Xu, Z; Zheng, QH | 1 |
| Qi, JS; Wang, CF; Wang, ZJ; Wu, MN; Xiao, Y; Yang, W; Zhang, J; Zhang, XM; Zhao, F; Zhou, F | 1 |
| Abid, MD; Chen, J; Feng, Z; Huang, H; Liu, X; Wan, L; Yan, H; Zhou, J | 1 |
| Eisenstein, M | 1 |
| Feng, J; Fu, Z; Li, Y; Luo, J; Tian, Q; Wang, Q; Yang, X; Yang, Y; Zhang, Q | 1 |
| Barrow, JC; Connolly, B; Cook, JJ; Fan, H; Gammage, L; Hargreaves, RJ; Harrison, ST; Hostetler, ED; Miller, P; Mulhearn, J; O'Malley, S; Sanabria-Bohórquez, S; Sur, C; Williams, DL; Wolkenberg, SE; Zeng, Z | 1 |
| Huttunen, HJ; Kysenius, K; Nykänen, NP; Sakha, P; Tammela, P | 1 |
| Chen, K; Cheng, AC; Dineen, TA; Epstein, O; Fremeau, RT; Graceffa, R; Hickman, D; Huang, H; Kiang, YH; La, DS; Louie, S; Luo, Y; Patel, VF; Wahl, RC; Wen, PH; Whittington, DA; Wood, S | 1 |
| Baenziger, NL; Dalemar, LR; Jong, YJ; Seehra, K | 1 |
| Gimbrett, R; Priest, RG; Roberts, M; Steinert, J | 1 |
| da Cruz e Silva, EF; da Cruz e Silva, OA; Greengard, P; Zaia, CT | 1 |
| Buzsaki, G; Gage, FH; Mandel, RJ; Terry, RD; Thal, LJ | 1 |
| Bruno, G; Chase, TN; Cox, C; Fedio, P; Foster, N; Gillespie, M; Hare, TA; Mohr, E; Tamminga, C | 1 |
1 trial(s) available for oxazoles and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
GABA-agonist therapy for Alzheimer's disease.
Topics: Alzheimer Disease; Clinical Trials as Topic; gamma-Aminobutyric Acid; Humans; Isoxazoles; Middle Aged; Neuropsychological Tests; Oxazoles; Somatostatin | 1986 |
14 other study(ies) available for oxazoles and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
A Dual-Pronged Approach: A Ruthenium(III) Complex That Modulates Amyloid-β Aggregation and Disrupts Its Formed Aggregates.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Coordination Complexes; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Conformation; Neuroprotective Agents; Oxazoles; Protein Aggregates; Rats; Ruthenium; Structure-Activity Relationship; Tumor Cells, Cultured | 2022 |
Discovery of novel series of 2-substituted benzo[d]oxazol-5-amine derivatives as multi-target directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amines; Amnesia; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Discovery; Eels; Female; Horses; Humans; Ligands; Male; Mice; Molecular Structure; Neuroprotective Agents; Oxazoles; Rats; Rats, Wistar; Scopolamine; Structure-Activity Relationship | 2019 |
Radiosynthesis of a carbon-11 labeled tetrahydrobenzisoxazole derivative as a new PET probe for γ-secretase imaging in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Carbon Radioisotopes; Chromatography, Reverse-Phase; Humans; Oxazoles; Positron-Emission Tomography; Radiopharmaceuticals; Solid Phase Extraction | 2020 |
Xestospongin C, a Reversible IP3 Receptor Antagonist, Alleviates the Cognitive and Pathological Impairments in APP/PS1 Mice of Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Cognition; Disease Models, Animal; Hippocampus; Macrocyclic Compounds; Male; Maze Learning; Mice; Mice, Transgenic; Neurons; Neuroprotective Agents; Nootropic Agents; Oxazoles; Plaque, Amyloid | 2019 |
Berberine attenuates axonal transport impairment and axonopathy induced by Calyculin A in N2a cells.
Topics: Alzheimer Disease; Animals; Axonal Transport; Axons; Berberine; Cell Line, Tumor; Cell Shape; Malondialdehyde; Marine Toxins; Mice; Neurons; Oxazoles; Oxidative Stress; Phosphorylase b; Phosphorylation; Superoxide Dismutase; tau Proteins | 2014 |
Molecular biology: Remove, reuse, recycle.
Topics: Aging; Alzheimer Disease; Autophagy; Biomedical Research; Caloric Restriction; HIV; Humans; Longevity; Neoplasms; Oxazoles; Parkinson Disease; Phagosomes; Rilmenidine | 2014 |
Melatonin ameliorates Alzheimer-like pathological changes and spatial memory retention impairment induced by calyculin A.
Topics: Alzheimer Disease; Animals; Antioxidants; Behavior, Animal; Disease Models, Animal; Male; Malondialdehyde; Marine Toxins; Melatonin; Memory Disorders; Oxazoles; Oxidative Stress; Phosphorylation; Protein Phosphatase 2; Rats; Rats, Sprague-Dawley; tau Proteins | 2011 |
[18F]Fluoroazabenzoxazoles as potential amyloid plaque PET tracers: synthesis and in vivo evaluation in rhesus monkey.
Topics: Alzheimer Disease; Animals; Autoradiography; Brain; Fluorine Radioisotopes; Humans; Inhibitory Concentration 50; Macaca mulatta; Oxazoles; Plaque, Amyloid; Positron-Emission Tomography; Pyridines; Radiopharmaceuticals; Tissue Distribution | 2011 |
γ-Aminobutyric acid type A (GABAA) receptor activation modulates tau phosphorylation.
Topics: Alzheimer Disease; Animals; Cell Line, Tumor; Cyclin-Dependent Kinase 5; Cytoskeleton; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Marine Toxins; Mice; Naphthoquinones; Nerve Degeneration; Neuroblastoma; NIMA-Interacting Peptidylprolyl Isomerase; Oxazoles; Peptidylprolyl Isomerase; Phosphorylation; Protein Kinase Inhibitors; Protein Phosphatase 2; Purines; Rats; Receptors, GABA-A; Roscovitine; tau Proteins; Tauopathies | 2012 |
Structure- and property-based design of aminooxazoline xanthenes as selective, orally efficacious, and CNS penetrable BACE inhibitors for the treatment of Alzheimer's disease.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Brain; Cell Line; Crystallography, X-Ray; Drug Design; Humans; Models, Molecular; Molecular Structure; Oxazoles; Peptide Fragments; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Xanthenes | 2012 |
Bradykinin receptor modulation in cellular models of aging and Alzheimer's disease.
Topics: Aging; Alzheimer Disease; Blotting, Western; Cell Line; Electrophoresis, Polyacrylamide Gel; Fibroblasts; Humans; Lung; Male; Marine Toxins; Oxazoles; Phorbol Esters; Phosphoprotein Phosphatases; Phosphorylation; Protein Kinase C; Receptor, Bradykinin B2; Receptors, Bradykinin; Skin | 2002 |
Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders.
Topics: Alzheimer Disease; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; Benzamides; Humans; Moclobemide; Monoamine Oxidase Inhibitors; Oxazoles; Oxazolidinones; Panic Disorder; Phobic Disorders; Piperidines | 1995 |
Inhibition of protein phosphatase 1 stimulates secretion of Alzheimer amyloid precursor protein.
Topics: Aged; Alzheimer Disease; Amyloid; Amyloid Precursor Protein Secretases; Aspartic Acid Endopeptidases; Cantharidin; Cell Line; Endopeptidases; Enzyme Inhibitors; Ethers, Cyclic; Humans; Immunoblotting; Marine Toxins; Okadaic Acid; Oxazoles; Phorbol 12,13-Dibutyrate; Phosphoprotein Phosphatases; Prion Proteins; Prions; Protein Phosphatase 1; Protein Precursors | 1995 |
Nucleus basalis lesions fail to induce senile plaques in the rat.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Basal Ganglia; Choline O-Acetyltransferase; Disease Models, Animal; Electroencephalography; Ibotenic Acid; Learning; Male; Oxazoles; Rats; Rats, Inbred F344 | 1990 |